Clinical trial
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating…
NCT00126581 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00126581 |
|---|---|
| Title | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer |
| Official title | A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7 |
| Intervention type | Drug |
| Interventions | Carboplatin, Erlotinib, Erlotinib Hydrochloride, Paclitaxel |
| Enrollment | 188 |
| Start date | Aug 15, 2005 |
| Primary completion | Jun 30, 2010 |
| Completion | Nov 28, 2017 |
| First posted | Aug 4, 2005 |
| Last update posted | Aug 7, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: